At the news
? NEUTRALIMPACT 2/10 8-K filed May 28, 2026 at 09:01 ET
Vir Biotechnology filed an 8-K reporting the departure of board member and Audit Committee Chair Saira Ramasastry due to a business conflict, effective May 26, 2026, with no disagreement with the company. The board reduced its size from eight to seven members and appointed Robert More as Audit Committee Chair. The filing also summarizes the 2026 Annual Meeting results, where all three Class I director nominees were elected, the advisory vote on executive compensation passed, and Ernst & Young was ratified as auditor.
- Director Saira Ramasastry stepped down from the board and Audit Committee effective May 26, 2026, due to a business conflict, not due to any disagreement with the company.
- Board size reduced from eight to seven members.
- Robert More appointed as Audit Committee Chair.
- At the 2026 Annual Meeting, all three Class I director nominees (Robert More, Janet Napolitano, Elliott Sigal) were elected.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access